Unknown

Dataset Information

0

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.


ABSTRACT: Until recently, surgery was the only remaining choice for moderate to severe chronic ulcerative colitis patients who failed standard treatment or when it was not tolerated. Anti-TNF? treatment is a new, non-invasive option for the management of ulcerative colitis. The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with adalimumab/standard care and standard care alone in Poland.A Markov model was used to estimate the expected costs and effects of adalimumab/standard care and a standard care alone. For each treatment option, the costs and quality adjusted life years were calculated to estimate the incremental cost-utility ratio. The analysis was performed from the perspective of the Polish public payer and society over a 30-year time horizon. Different direct and indirect costs and utility values were assigned to the various model health states.The treatment of ulcerative colitis patients with adalimumab/standard care up to 1 year instead of a standard care alone resulted in 0.14 additional years of life with full health (QALYs). The incremental cost-utility ratio of adalimumab/standard care compared to the standard care alone is estimated to be 76,120 €/QALY gained from NHF perspective and 71,457 €/QALY gained from social perspective.The biologic treatment of ulcerative colitis patients with adalimumab/standard care is more effective but also more costly compared with standard care alone.

SUBMITTER: Stawowczyk E 

PROVIDER: S-EPMC5055904 | biostudies-other | 2016 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.

Stawowczyk Ewa E   Kawalec Paweł P   Pilc Andrzej A  

European journal of clinical pharmacology 20160806 11


<h4>Purpose</h4>Until recently, surgery was the only remaining choice for moderate to severe chronic ulcerative colitis patients who failed standard treatment or when it was not tolerated. Anti-TNFα treatment is a new, non-invasive option for the management of ulcerative colitis. The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with adalimumab/standard care and standard care alone in Poland.<h4>Methods</h4>  ...[more]

Similar Datasets

| S-EPMC4975491 | biostudies-literature
| S-EPMC5569655 | biostudies-literature
| S-EPMC10760906 | biostudies-literature
| S-EPMC11362413 | biostudies-literature
| S-EPMC9494926 | biostudies-literature
| S-EPMC5016577 | biostudies-other
| S-EPMC10869650 | biostudies-literature
| S-EPMC4917292 | biostudies-literature
| S-EPMC4223868 | biostudies-other
| S-EPMC4831381 | biostudies-other